首页|Immune checkpoint inhibitors break whose heart?Perspectives from cardio-immuno-oncology

Immune checkpoint inhibitors break whose heart?Perspectives from cardio-immuno-oncology

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Immune checkpoint inhibitors(ICIs)are monoclonal antibody antagonists,which can block cytotoxic T lymphocyte antigen-4(CTLA-4),programmed death-1/ligand-1(PD-1/PD-L1)pathways,and other molecules exploited by tumor cells to evade T cell-mediated im-mune response.ICIs have transformed the treatment landscape for various cancers due to their amazing efficacy.Many anti-tumor therapies,including targeted therapy,radiotherapy,and chemotherapy,combine ICIs to make the treatment more effective.However,the off-target immune activation caused by ICIs may lead to a broad spectrum of immune-related adverse events(irAEs)affecting multiple organ systems.Among irAEs,cardiotoxicity induced by ICIs,uncommon but fatal,has greatly offset survival benefits from ICIs,which is heartbreaking for both patients and clinicians.Consequently,such cardiotoxicity requires special vigilance,and it has become a common challenge both for patients and clinicians.This article reviewed the clinical manifestations and influence of cardiotoxicity from the view of patients and clini-cians,elaborated on the underlying mechanisms in conjunction with animal studies,and then attempted to propose management strategies from a cardio-immuno-oncology multidisci-plinary perspective.

Cancer managementCardio-immuno-oncology multidisciplinaryCardiotoxicityImmune checkpoint inhibitorsImmune tolerance

Yingying He、Hui Yu、Shuang Dai、Miao He、Ling Ma、Zihan Xu、Feng Luo、Li Wang

展开 >

Oncology Department,Deyang People's Hospital,Deyang,Sichuan 618000,China

Department of Medical Oncology,Lung Cancer Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610000,China

Cardiovascular Department,Mianyang Central Hospital,Mianyang,Sichuan 621000,China

Department of Rheumatology and Immunology,Deyang People's Hospital,Deyang,Sichuan 618000,China

展开 >

Deyang Science and Technology Foundation(Sichuan,China)

2019SZ120

2024

10.1016/j.gendis.2023.01.024

基因与疾病(英文)

基因与疾病(英文)

ISSN：
年,卷(期)：2024.11(2)
  • 124